West Pharmaceutical Services (WST) Non-Current Debt (2009 - 2026)

West Pharmaceutical Services has disclosed Non-Current Debt across 18 years of filings, most recently posting $202.9 million for Q2 2026.

• In Q2 2026, Non-Current Debt changed 0.15% year-over-year to $202.9 million; the TTM figure through Jun 2026 stood at $202.9 million (changed 0.15% YoY), while the FY2025 annual figure was $202.8 million, changed 0.1% from the prior year.
• Non-Current Debt came in at $202.9 million for Q2 2026 at West Pharmaceutical Services, roughly flat from $202.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $252.5 million in Q1 2022 to a low of $202.6 million in Q3 2024.
• Average Non-Current Debt over 5 years is $210.4 million, with a median of $206.0 million recorded in 2024.
• Year-over-year, Non-Current Debt fell 17.59% in 2022 and increased 0.15% in 2026.
• Over 5 years, Non-Current Debt stood at $208.9 million in 2022, then slipped by 1.01% to $206.8 million in 2023, then retreated by 2.03% to $202.6 million in 2024, then gained by 0.1% to $202.8 million in 2025, then climbed by 0.05% to $202.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $202.9 million in Q2 2026, $202.8 million in Q1 2026, and $202.8 million in Q4 2025.